Numeta G16e (Valine, Ornithine Hydrochloride, Alanine, Arginine, Cysteine, Histidine, Isoleucine, Leucine, Methio)

Numeta G16e is an amino acid‑based parenteral nutrition product that provides essential nutrients for patients with increased metabolic demand or impaired oral intake.

• Critical care: Supplies balanced amino acids to support protein synthesis and nitrogen balance.
• Post‑operative recovery: Helps maintain lean body mass during the catabolic phase after surgery.
• Severe malnutrition: Provides a complete amino acid profile for patients unable to meet needs orally.
• Gastrointestinal failure : Delivers nutrition when enteral feeding is contraindicated.
• Burn injuries : Supports high protein requirements in extensive burn patients.

• Numeta G16e delivers a mixture of essential and non‑essential amino acids directly into the bloodstream, bypassing the gastrointestinal tract. The amino acids become substrates for protein synthesis, replenish nitrogen stores, and support cellular metabolism, thereby correcting deficits that arise from catabolism, trauma, or inadequate intake.

Adverse reactions are generally related to the intravenous route and the amino‑acid composition.

Common Side Effects

• Hyperglycaemia: Elevated blood glucose levels, especially in diabetic patients.
• Electrolyte disturbances: Shifts in potassium, phosphate or magnesium concentrations.
• Mild infusion‑site reactions: Redness, warmth or discomfort at the catheter site.
• Transient increase in serum urea nitrogen.
• Nausea or mild gastrointestinal upset.

Serious or Rare Side Effects

• Anaphylaxis: Acute, potentially life‑threatening hypersensitivity reaction.
• Severe hyperosmolar reactions: Marked fluid shifts leading to edema or pulmonary congestion.
• Metabolic acidosis: Significant drop in blood pH due to amino‑acid metabolism.
• Hepatic dysfunction: Elevated liver enzymes in susceptible individuals.
• Sepsis related to catheter contamination.
• Thrombophlebitis: Inflammation of the vein with clot formation.

When using Numeta G16e, clinicians should assess patient-specific factors and monitor relevant parameters.

• Renal function: Adjust dosing in patients with impaired kidney function.
• Hepatic function: Monitor liver enzymes in patients with liver disease.
• Fluid balance: Track input‑output to avoid overload in volume‑sensitive patients.
• Electrolyte monitoring: Check serum electrolytes regularly during therapy.
• Glycaemic control: Observe blood glucose in diabetic or hyperglycaemic patients.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Numeta G16e may interact with other intravenous solutions or medications administered through the same line.

Major Interactions (Avoid)

• High‑dose glucose solutions: Can exacerbate hyperglycaemia when combined with amino‑acid infusions.
• Calcium‑containing admixtures: May precipitate insoluble salts with certain amino acids.

Moderate Interactions (Monitor Closely)

• Diuretics: May increase electrolyte loss, requiring closer monitoring.
• Anticoagulants: Altered protein synthesis can affect coagulation factor levels.
• Beta‑blockers: May mask tachycardia that can signal infusion reactions.
• Steroids: Enhance protein catabolism, potentially reducing the net benefit of amino‑acid supplementation.
• Immunosuppressants: May affect wound‑healing response while on parenteral nutrition.